Drug delivery across the blood–brain barrier: why is it difficult? how to measure and improve it?

Abstract

The development of drugs that act in the CNS has been significantly impeded by the difficulty of delivering them across the blood–brain barrier (BBB). This article aims to provide the reader with a critical overview of important issues in the discovery and development of drugs that need to enter the brain to elicit pharmacological activity, focusing particularly on i) the role of drug transporters in brain permeation and how to manipulate them to enhance drug brain bioavailability; ii) the successful application, limitations and challenges of commonly used in vitro and in vivo methodologies for measuring drug transport across the BBB, and iii) a discussion of recently developed strategies (e.g., modulation of efflux transporters by chemical inhibitors and the employment of delivery vectors taking advantage of native transport systems at the BBB) for facilitating drug penetration into the brain.

Keywords::

• blood–brain barrier
• brain capillary endothelial cells
• Caco-2 cell
• cell penetrating peptides
• efflux
• Madin-Darby canine kidney cell
• P-glycoprotein
• P-glycoprotein inhibitor
• pegylated immunoliposome
• receptor-mediated transport
• transporter

Acknowledgements

The authors appreciate the three anonymous reviewers’ suggestive comments and apologise for not being able to cite many important publications because of space constraints.

Notes